Methods of treating diabetes mellitus
First Claim
Patent Images
1. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising:
- orally administering to the human patient between about 0.05 and 10 mg per kilogram body weight of an insulin polypeptide-oligomer conjugate comprising the structure of Formula III;
Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;
X is a moiety which forms an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond;
m is between 1 and 24;
n is between 1 and 50; and
R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;
to the human patient within one hour prior to ingestion of a meal or contemporaneously with ingestion of a meal by the human patient in order to treat diabetes mellitus in the human patient, wherein the effective amount of the conjugate of Formula III is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
4 Assignments
0 Petitions
Accused Products
Abstract
Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate” the liver, potentially restoring normal glucose homeostasis to individuals suffering from diabetes mellitus.
-
Citations
61 Claims
-
1. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising:
-
orally administering to the human patient between about 0.05 and 10 mg per kilogram body weight of an insulin polypeptide-oligomer conjugate comprising the structure of Formula III;
Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;X is a moiety which forms an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to the human patient within one hour prior to ingestion of a meal or contemporaneously with ingestion of a meal by the human patient in order to treat diabetes mellitus in the human patient, wherein the effective amount of the conjugate of Formula III is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)
-
-
56. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising:
-
orally administering to the human patient an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III;
Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to treat diabetes mellitus in the human patient, wherein the effective amount of the insulin polypeptide-oligomer conjugate is administered so that it provides an insulin drug concentration in portal vein blood between about 10 and 1,000 U/ml within about 60 minutes of administration.
-
-
57. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising:
-
orally administering to the human patient an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III;
Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to the human patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide-oligomer conjugate is administered so that it stabilizes peripheral glucose concentration to within about +/−
50 percent of an average peripheral glucose concentration measured over about a one hour time period beginning within about 30 minutes after administration. - View Dependent Claims (61)
-
-
58. A method of treating diabetes mellitus in a patient in need of such treatment, said method comprising:
-
orally administering to the human patient between about 0.05 and 10 mg per kilogram body weight of an insulin polypeptide-oligomer conjugate comprising the structure of Formula III;
Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to the human patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide-oligomer conjugate is administered so that it reduces hepatic glucose production in the patient by at least about 25 percent when compared to hepatic glucose production in the human patient without administration. - View Dependent Claims (59)
-
-
60. A method of treating diabetes mellitus in a human patient in need of such treatment, said method comprising:
-
orally administering to the human patient between about 0.05 and 10 mg per kilogram body weight of an effective amount of a insulin polypeptide-oligomer conjugate comprising the structure of Formula III;
Insulin polypeptide-X(CH2)m(OC2H4)nOR
(III)
wherein;X is an ester moiety, a thio-ester moiety, an ether moiety, a carbamate moiety, a thio-carbamate moiety, a carbonate moiety, a thio-carbonate moiety, an amide moiety, a urea moiety, or a covalent bond; m is between 1 and 24; n is between 1 and 50; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; to the human patient in order to treat diabetes mellitus in the patient, wherein the effective amount of the insulin polypeptide-oligomer conjugate is administered so that at least about 25 percent of post-prandial glucose resulting from ingestion of a meal by the patient is hepatically absorbed within about 120 minutes of ingestion of the meal by the human patient.
-
Specification